Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$95.36
-$1.30(-1.34%)
At close: 4:00 PM EDT
$95.36
-$1.30(-1.34%)
Day’s Range― - ―
52-Week Range$28.66 - $122.21
Previous CloseN/A
Volume1.00M
Average Volume (3M)1.06M
Market Cap
$12.77B
Enterprise Value$9.99K
Total Cash (Recent Filing)$308.20M
Total Debt (Recent Filing)$9.42M
Price to Earnings (P/E)228.9
Beta0.55
Next Earnings
Nov 04, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding108,098,400
10 Day Avg. Volume1,209,033
30 Day Avg. Volume1,056,039
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$141.00Price Target Upside47.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.03
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial ExpansionStrong revenue growth across Korlym and newly launched Lifyorli indicates expanding commercial scale. The raised guidance and oncology contribution suggest Corcept is building a broader revenue base beyond its legacy endocrinology franchise.
Strong Balance Sheet And Cash GenerationMinimal leverage and substantial cash generation provide flexibility to fund clinical development, commercialization and potential regulatory requirements without relying heavily on external financing. Cash-backed earnings also strengthen resilience through development cycles.
Pipeline And Regulatory ExpansionA successful relacorilant approval could expand Corcept’s Cushing’s syndrome franchise with a second important therapy. Multiple oncology and non-oncology programs further create opportunities to extend cortisol-modulation expertise across larger indications.
Bears Say
Profitability And Cash-Flow CompressionAlthough gross margins remain exceptional, declining net profitability and cash generation indicate rising pressure below gross profit. If sustained, this could reduce internally funded investment capacity and make execution of the expanding pipeline less efficient.
Relacorilant Regulatory RiskRelacorilant is central to Corcept’s planned expansion of the Cushing’s franchise, but the prior complete response letter shows unresolved execution risk. A further delay or rejection could limit growth, prolong development spending and weaken pipeline credibility.
Revenue Concentration And Launch DurabilityThe business remains dependent on Korlym while Lifyorli is still early and lacks enough follow-up to establish treatment duration. Concentration in a limited product base increases exposure to competitive, reimbursement, regulatory and adoption risks.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $122.21 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $12.77B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 76 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Jul 29, 2026. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.024 by $0.336.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.81.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 108,098,400 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.36 in its last earnings report, beating expectations of $0.024. Following the earnings report the stock price went up 27.294%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$141.00 (47.86% Upside)
$141.00 (47.86% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum and meaningful clinical and regulatory progress: strong Q2 financials (+32% revenue growth), a fast and well‑covered Lifyorli launch with survival data supporting uptake, record Korlym prescribing driven by shifting clinical awareness, and multiple near‑term trial readouts. Offsetting these positives are residual regulatory risk for relacorilant (prior CRL, PDUFA Dec 17, 2026), tolerability concerns and mixed statistical significance in early ALS results, and the usual clinical/regulatory execution risks across the pipeline. On balance, the positive financial performance, rapid oncology launch, and pipeline catalysts outweigh the noted risks.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$141.00
▲(47.86% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.77% Insiders
14.97% Mutual Funds
16.58% Other Institutional Investors
36.46% Public Companies and
Individual Investors